After Only a Few Days, Trump’s Drug Plan Is Already Dead

Richard B. Levine/Levine Roberts/Newscom via ZUMA

Do you remember that plan from the Trump administration about making pharmaceutical companies cut the price of some of their most expensive drugs to match prices in Europe? It was, oh, let’s just check here—well, it was last week. An eternity in Trump time, I know.

Anyway, the fatal flaw in the plan is that it’s all about how much Medicare pays for drugs, but Medicare has no leverage. It can negotiate all it wants, but in the end it’s required to cover virtually all drugs and it’s required to pay whatever the manufacturer says. It’s not allowed to drop coverage of a drug because it’s too expensive.

Still, you’d expect drug companies to be publicly polite about the whole thing, if only for the sake of PR. But David Lazarus of the LA Times reports that they aren’t even bothering to pretend. Pfizer’s CEO, Ian Read, announced a 45 percent earnings increase this week and was then asked if it would reconsider price hikes in January due to Trump’s proposal:

“I expect our approach by the end of year will be, what I would characterize as business as normal,” Read answered during a conference call with analysts. “We price to the marketplace,” he said. “We price competitively, and we will make those decisions towards the end of the year and early in January.”

In other words, no more Mr. Nice Guy. Pfizer will once again reach as deeply as possible into people’s pockets, regardless of what President Trump might want. Because let’s face it: For all his talk of drug companies “getting away with murder,” Trump has been all bark and no bite when it comes to sky-high drug prices. And the industry knows it.

In fairness to Trump,¹ there’s little he can do on his own. Only Congress can change the law that requires Medicare to cover everything, and Trump has never demonstrated either the desire or the ability to sway Congress. Not that it would probably matter: congressional Republicans just won’t do it, no matter how much their constituents might like the idea. So in only a few days, Trump’s plan is already effectively dead, and he’s unlikely to care much about it after the election is over.

¹See? I can be fair to Trump once in a while.


as we head into 2020 is whether politics and media will be a billionaires’ game, or a playing field where the rest of us have a shot. That's what Mother Jones CEO Monika Bauerlein tackles in her annual December column—"Billionaires Are Not the Answer"—about the state of journalism and our plans for the year ahead.

We can't afford to let independent reporting depend on the goodwill of the superrich: Please help Mother Jones build an alternative to oligarchy that is funded by and answerable to its readers. Please join us with a tax-deductible, year-end donation so we can keep going after the big stories without fear, favor, or false equivalency.


as we head into 2020 is whether politics and media will be a billionaires’ game, or a playing field where the rest of us have a shot.

Please read our annual column about the state of journalism and Mother Jones' plans for the year ahead, and help us build an alternative to oligarchy by supporting our people-powered journalism with a year-end gift today.

We Recommend


Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.


Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.


We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.